| Identification | Back Directory | [Name]
Prasinezumab | [CAS]
1960462-19-4 | [Synonyms]
Prasinezumab
Research Grade Prasinezumab
Research Grade Prasinezumab(DHE22002) |
| Hazard Information | Back Directory | [Uses]
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research[1]. | [IC 50]
α-synuclein Aggregation | [References]
[1] Gennaro Pagano, et al. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Front Neurol. 2021 Oct 1;12:705407. DOI:10.3389/fneur.2021.705407 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|